Not admitted · Commitment (own venture)
Rules 1.1.0 · as of 14 Sep 2026
Christian Angermayer · Said 29 Nov 2021 · angermayer-0191
Quote
Commitment (own venture)
“Being confident all along about the results for their phase 2b trial, COMPASS management has shown conviction and already prepared everything for their phase 3 study of psilocybin in TRD, which is anticipated to launch in 2022.”
In his own post explaining why atai raised its Compass Pathways stake above 20%, Angermayer says Compass has everything ready for the first Phase 3 study of psilocybin in treatment-resistant depression and puts the launch in 2022.
The forecaster's own organization can make the outcome happen by its own decision: clinic openings, product launches, hires, trial starts, filings by their own company. Listed in the commitments table, never scored.